Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro
Abstract
Purpose 20(S)-Camptothecin (CAM), topotecan (TPT, active ingredient in Hycamtin) and 9-amino-20(S)-camptothecin (9AC) are topoisomerase I inhibitors that cause similar dose-limiting toxicities to rapidly renewing tissues, such as hematopoietic tissues, in humans, mice, and dogs. However, dose-limiting toxicity occurs at tenfold lower doses in humans than in mice. The purpose of the current study was to determine whether hematopoietic progenitors of the myeloid lineage from humans, mice, and dogs exhibit the differential sensitivity to these compounds that is evident in vivo.Methods Drug-induced inhibition of in vitro colony formation by a myeloid progenitor in human, murine, and canine marrow colony-forming unit-granulocyte/macrophage (CFU-GM) provided the basis for interspecies comparisons at concentrations which inhibited colony formation by 50% (IC50) and 90% (IC90).Results Murine IC90 values were 2.6-, 2.3-, 10-, 21-, 5.9-, and 11-fold higher than human values for CAM lactone (NSC-94600) and sodium salt (NSC-100880), TPT (NSC-609699), and racemic (NSC-629971), semisynthetic and synthetic preparations (NSC-603071) of 9AC, respectively. In contrast, canine IC90 values were the same as, or lower than, the human IC90 values for all six compounds.Conclusions The greater susceptibility of humans and dogs to the myelotoxicity of camptothecins, compared to mice, was evident in vitro at the cellular level. Differential sensitivity between murine and human myeloid progenitors explains why the curative doses of TPT and 9AC in mice with human tumor xenografts are not achievable in patients. Realizing the curative potential of these compounds in humans will require the development of therapies to increase drug tolerance of human CFU-GM at least to a level equal to that of murine CFU-GM. Because these interspecies differences are complicated by species-specific effects of plasma proteins on drug stability, not all in vitro assay conditions will yield results which can contribute to the development of such therapies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Toxicity data in mice should be interpreted with caution because murine and human bone marrow differ in sensitivity to oncolytics.
“Toxicity data in mice should be interpreted with caution because differential sensitivity to oncolytics between murine and human bone marrow has been reported.7,15”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [15]
Cites
Still being checked.
Cited by
Sorted by citations
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. G. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 711 · see citing works
García‐Carbonero, R., & Supko, J. G. (2002) · PubMed · Cited by 495 · see citing works
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 311 · see citing works
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · see citing works
Self-citationNext generation topoisomerase I inhibitors: Rationale and biomarker strategies
Teicher, B. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.016 · Cited by 175 · see citing works
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
Pommier, Y. G., & Cushman, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0706 · Cited by 162 · see citing works
Yohe, S. T., Herrera, V. L. M., Colson, Y. L., & Grinstaff, M. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.047 · Cited by 157 · see citing works
Pessina, A. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg188 · Cited by 143 · see citing works
Hartley, J. A., Spanswick, V. J., Brooks, N. A., Clingen, P. H., McHugh, P. J., Hochhauser, D., Pedley, R. B., Kèlland, L. R., Alley, M. C., Schultz, R. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2941 · Cited by 137 · see citing works
Self-citationTransvascular drug delivery in solid tumors
Fan, Y. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80042-8 · Cited by 132 · see citing works
Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
Knight, V., Koshkina, N. V., Waldrep, J. C., Giovanella, B. C., & Gilbert, B. E. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050965 · Cited by 102 · see citing works
Miknyoczki, S. J., Chang, H., Grobelny, J. V., Pritchard, S., Worrell, C. S., McGann, N., Ator, M. A., Husten, J., Deibold, J., Hudkins, R. L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0062 · Cited by 101 · see citing works
Self-citationCamptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine
Koo, O. M. Y., Rubinstein, I., & Önyüksel, H. (2005) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2004.11.002 · Cited by 99 · see citing works
In Vitro Human Tissue Models in Risk Assessment: Report of a Consensus-Building Workshop
MacGregor, J. T. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.1.17 · Cited by 98 · see citing works
Leu, Y.-L., Roffler, S. R., & Chern, J. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990124q · Cited by 78 · see citing works
Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests
Parchment, R. E., Gordon, M., Grieshaber, C. K., Sessa, C., Volpe, D. A., & Ghielmini, M. E. G. (1998) · Annals of Oncology · doi:10.1023/a:1008245906772 · Cited by 72 · see citing works
Self-citationCesare, M. D., Pratesi, G., Perego, P., Carenini, N., Tinelli, S., Merlini, L., Penco, S., Pisano, C., Bucci, F., Vesci, L., et al. (2001) · PubMed · Cited by 68 · see citing works
Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data
Rubahamya, B., Dong, S., & Thurber, G. M. (2024) · Science Advances · doi:10.1126/sciadv.adk1894 · Cited by 64 · see citing works
Wong, P., Cheong, W.-F., Shu, M., Teh, C.-H., Chan, K., & AbuBakar, S. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.07.001 · Cited by 64 · see citing works
Best Practices for Evaluation of Bone Marrow in Nonclinical Toxicity Studies
Reagan, W. J., Irizarry‐Rovira, A. R., Poitout‐Belissent, F., Bolliger, A. P., Ramaiah, S. K., Travlos, G. S., Walker, D. B., Bounous, D. I., Walter, G. L., & Bone Marrow Working Group of ASVCP/STP (2011) · Toxicologic Pathology · doi:10.1177/0192623310396907 · Cited by 64 · see citing works
Derakhshandeh, K. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s11586 · Cited by 60 · see citing works
Animal models for studying the action of topoisomerase I targeted drugs
Thompson, J., Stewart, C. F., & Houghton, P. J. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00143-2 · Cited by 60 · see citing works
Panetta, J. C., Schaiquevich, P. S., Santana, V. M., & Stewart, C. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1243 · Cited by 59 · see citing works
Preclinical antitumor activity of XK469 (NSC 656889)
LoRusso, P. M., Parchment, R. E., Demchik, L. L., Knight, J., Polin, L., Dzubow, J., Behrens, C. H., Harrison, B., Trainor, G. L., & Corbett, T. H. (1998) · Investigational New Drugs · doi:10.1023/a:1006206814025 · Cited by 57 · see citing works
Self-citationGenz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment
Kurtzberg, L. S., Roth, S., Krumbholz, R. D., Crawford, J., Bormann, C., Dunham, S., Yao, M., Rouleau, C., Bagley, R. G., Yu, X., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0542 · Cited by 52 · see citing works
Yousefpour, P., McDaniel, J. R., Prasad, V., Ahn, L., Li, X., Subrahmanyan, R., Weitzhandler, I., Suter, S. E., & Chilkoti, A. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03558 · Cited by 52 · see citing works
Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery
Gao, J., Ming, J., He, B., Fan, Y., Gu, Z., & Zhang, X. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.01.016 · Cited by 51 · see citing works
Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49 · see citing works
Pharmacodynamic model of topotecan-induced time course of neutropenia.
Zamboni, W. C., D’Argenio, D. Z., Stewart, C. F., MacVittie, T., Delauter, B. J., Farese, A. M., Potter, D. M., Kubat, N. M., Tubergen, D. G., & Egorin, M. J. (2001) · PubMed · Cited by 48 · see citing works
The Development of Camptothecin Analogs in Childhood Cancers
Bomgaars, L. R., Berg, S. L., & Blaney, S. M. (2001) · The Oncologist · doi:10.1634/theoncologist.6-6-506 · Cited by 46 · see citing works
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Csizmar, C. M., Saliba, A. N., Swisher, E. M., & Kaufmann, S. H. (2021) · Cancers · doi:10.3390/cancers13246385 · Cited by 45 · see citing works
Zu, Y., Wang, D., Zhao, X., Jiang, R., Zhang, Q., Zhao, D., Li, Y., Zu, B., & Sun, Z. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074237 · Cited by 42 · see citing works
Why drugs fail: of mice and men revisited.
Takimoto, C. H. M. (2001) · PubMed · Cited by 42 · see citing works
The Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M. R., Elmi, A. N., Pandya, P. H., Bijangi‐Vishehsaraei, K., Ding, J., Stamatkin, C. W., Cohen‐Gadol, A., & Pollok, K. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 43 · see citing works
In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review
Teicher, B. A. (2008) · Toxicologic Pathology · doi:10.1177/0192623308329473 · Cited by 39 · see citing works
Kurtzberg, L. S., Battle, T. E., Rouleau, C., Bagley, R. G., Agata, N., Yao, M., Schmid, S. M., Roth, S., Crawford, J., Krumbholz, R. D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0568 · Cited by 37 · see citing works
Best practices for evaluation of bone marrow in nonclinical toxicity studies
Reagan, W. J., Irizarry‐Rovira, A. R., Poitout‐Belissent, F., Bolliger, A. P., Ramaiah, S. K., Travlos, G. S., Walker, D. B., Bounous, D. I., Walter, G. L., & Bone Marrow Working Group of ASVCP/STP (2011) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2011.00323.x · Cited by 37 · see citing works
Gao, S.-Q., Lu, Z., Kopečková, P., & Kopec̆ek, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.024 · Cited by 35 · see citing works
Spielmann, H., Бочков, Н. П., Costa, L. G., Gribaldo, L., Guillouzo, A., Heindel, J. J., Karol, M., Parchment, R. E., Pfaller, W., Peraita, P. P., et al. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106427 · Cited by 34 · see citing works
Self-citationMasubuchi, N., May, R. D., & Atsumi, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0721 · Cited by 33 · see citing works
Self-citationHumanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity
Cai, S., Wang, H., Bailey, B., Ernstberger, A., Juliar, B. E., Sinn, A. L., Chan, R. J., Jones, D. R., Mayo, L. D., Baluyut, A. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1959 · Cited by 32 · see citing works
Wu, X., Li, H., Song, S., Zhang, R., & Hou, W. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.043 · Cited by 32 · see citing works
Alternative Testing Systems for Evaluating Noncarcinogenic, Hematologic Toxicity
Parchment, R. E. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106541 · Cited by 32 · see citing works
Self-citationAlbella, B., Faircloth, G. T., Lázaro, L. L., Guzmán, C., Jimeno, J. M., & Bueren, J. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00245-3 · Cited by 31 · see citing works
Chattopadhyay, S., Stewart, A. L., Mukherjee, S., Huang, C., Hartwell, K. A., Miller, P. G., Subramanian, R., Carmody, L., Yusuf, R. Z., Sykes, D. B., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.017 · Cited by 28 · see citing works
The Clinical Development of 9‐Aminocamptothecin
Takimoto, C. H. M., & THOMAS, R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07041.x · Cited by 29 · see citing works
Klein, C. E., Kastrissios, H., Miller, A. A., Hollis, D. R., Yu, D., Rosner, G. L., Grinblatt, D. L., Larson, R. A., & Ratain, M. J. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0023-6 · Cited by 28 · see citing works
Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents
Volpe, D. A., & Warren, M. K. (2003) · Toxicology in Vitro · doi:10.1016/s0887-2333(03)00012-2 · Cited by 27 · see citing works
In Vitro Tests for Haematotoxicity: Prediction of Drug-induced Myelosuppression by the CFU-GM Assay
Pessina, A., Albella, B., Bayo, M., Bueren, J. A., Brantom, P., Casati, S., Croera, C., Parchment, R. E., Parent‐Massin, D., Schoeters, G. E. R., et al. (2002) · Alternatives to Laboratory Animals · doi:10.1177/026119290203002s11 · Cited by 25 · see citing works
Self-citationGemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy
Karampelas, T., Skavatsou, E., Argyros, O., Fokas, D., & Tamvakopoulos, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00961 · Cited by 25 · see citing works
Yamashita, F., Komoto, I., Oka, H., Kuwata, K., Takeuchi, M., Nakagawa, F., Yoshisue, K., & Chiba, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2805-9 · Cited by 24 · see citing works
Selective Drug Resistant Human Osteosarcoma Cell Lines
Burns, B. S., Edin, M. L., Lester, G. E., Tuttle, H. G., Wall, M. E., Wani, M. C., & Bos, G. D. (2001) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200102000-00030 · Cited by 24 · see citing works
14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment
Duan, J.-X., Cai, X., Meng, F., Sun, J. D., Liu, Q., Jung, D. T., Jiao, H., Matteucci, J., Jung, B., Bhupathi, D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101354u · Cited by 23 · see citing works
Ki, D. H., Oppel, F., Durbin, A. D., & Look, A. T. (2019) · Oncogene · doi:10.1038/s41388-019-0965-5 · Cited by 21 · see citing works
Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program
Houghton, P. J., Lock, R. B., Carol, H., Morton, C. L., Gorlick, R. G., Kolb, E. A., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23016 · Cited by 18 · see citing works
Gao, S.-Q., Sun, Y., Kopečková, P., Peterson, C. M., & Kopec̆ek, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9465-3 · Cited by 17 · see citing works
Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity
Hassan, S. B., Haglund, C., leskog, A., Larsson, R., & Lindhagen, E. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.03.009 · Cited by 16 · see citing works
Kuppens, I. E. L. M., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.017 · Cited by 16 · see citing works
Topoisomerase I inhibitors and drug resistance
Parchment, R. E., & Pessina, A. (1998) · Cytotechnology · doi:10.1023/a:1008008719699 · Cited by 15 · see citing works
Self-citationKizaki, M., Muto, A., Kinjo, K., Ueno, H., & Ikeda, Y. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.24.1906 · Cited by 14 · see citing works
Preclinical in vitro evaluation of hematotoxicity of the cisplatin–procaine complex DPR
Viale, M., Minetti, S., Ottone, M., Lerza, R., Parodi, B., & Pannacciulli, I. M. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200302000-00010 · Cited by 13 · see citing works
Human tumor xenografts and mouse models of human tumors: re-discovering the models
Teicher, B. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903380430 · Cited by 12 · see citing works
Akilov, O. E., Wu, M. X., Jin, Y., Zhou, Z., Geskin, L. J., Falo, L. D., & Hasan, T. G. (2011) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2011.00578.x · Cited by 12 · see citing works
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
Kurtzberg, L. S., Roth, S. D., Bagley, R. G., Rouleau, C., Yao, M., Crawford, J. L., Krumbholz, R. D., Schmid, S. M., & Teicher, B. A. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0959-z · Cited by 11 · see citing works
CFU‐GM Assay for Evaluation of Drug Myelotoxic Activity
Pessina, A., & Bonomi, A. (2007) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx2002s34 · Cited by 11 · see citing works
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
Bagley (2009) · International Journal of Oncology · doi:10.3892/ijo_00000260 · Cited by 11 · see citing works
Tomaszewski, J. E., Smith, A. C., Covey, J. M., Donohue, S. J., Rhie, J. K., & Schweikart, K. M. (2002) · Elsevier eBooks · doi:10.1016/b978-012072651-6/50018-8 · Cited by 11 · see citing works
Self-citationMoneta, D., Geroni, C., Valota, O., Grossi, P., de Jonge, M. J. A., Brughera, M., Colajori, E., Ghielmini, M. E. G., & Sessa, C. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00812-2 · Cited by 11 · see citing works
Cavallini, M., Antonioli, B., Gazzola, R., Tosca, M. C., Galuzzi, M., Rapisarda, V., Ciancio, F., & Marazzi, M. (2013) · European Journal of Plastic Surgery · doi:10.1007/s00238-013-0855-y · Cited by 10 · see citing works
Alternative methods in toxicology: CFU assays application, limitation and future prospective
Yadav, N. K., Shukla, P., Omer, A., Singh, P. C., & Singh, R. K. (2015) · Drug and Chemical Toxicology · doi:10.3109/01480545.2014.994217 · Cited by 10 · see citing works
Horn, T. L., Harder, J. B., Johnson, W. D., Curry, P. T., Parchment, R. E., Morrissey, R. L., Mellick, P. W., Calis, K. A., Gold, P. W., Rice, K. C., et al. (2008) · Toxicology · doi:10.1016/j.tox.2008.03.002 · Cited by 9 · see citing works
Self-citationFerlini, C., Distefano, M., Pierelli, L., Bonanno, G., Fattorossi, A., Battaglia, A., Mancuso, S., & Scambia, G. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-153.x · Cited by 8 · see citing works
Tsakalozou, E., Adane, E. D., Liang, Y., Arnold, S. M., & Leggas, M. L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2472-2 · Cited by 7 · see citing works
Review : Topoisomerase I inhibitors: 1. Topotecan
Relias, V., & Skirvin, J. A. (1997) · Journal of Oncology Pharmacy Practice · doi:10.1177/107815529700300401 · Cited by 7 · see citing works
Rajput, R. B. P. S. (2013) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000158 · Cited by 6 · see citing works
Analyses of the combination of 6-MP and dasatinib in cell culture
Kaur, G., Behrsing, H. P., Parchment, R. E., Millin, M. D., & Teicher, B. A. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1930 · Cited by 6 · see citing works
Self-citationKumar, S., Mokhtari, R. B., Yeger, H., & Baruchel, S. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.722077 · Cited by 6 · see citing works
Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828
Lindhagen, E., Hjarnaa, P. V., Friberg, L. E., Latini, S., & Larsson, R. (2004) · Drug Development Research · doi:10.1002/ddr.10353 · Cited by 5 · see citing works
Guo, L., Hamre, J. R., Davis, M., & Parchment, R. E. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.11.017 · Cited by 4 · see citing works
Self-citationIto, R., Nagai, D., Igo, N., Okuda, Y., Sekine, K., Ichimura, E., Katano, I., Mizushima, T., Goto, M., Ohnishi, Y., et al. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.09.013 · Cited by 4 · see citing works
KOUCHI, Y., Maeda, Y., Ohuchida, A., & Nomura, N. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00206-0 · Cited by 4 · see citing works
Natural Product Scaffolds in Cancer Therapy
Mang, C. F., & Haustedt, L. O. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4654-5_6 · Cited by 4 · see citing works
Failure Modes in Anticancer Drug Discovery and Development
Walgren, R. A., & Slapak, C. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00019-x · Cited by 3 · see citing works
Behrsing, H. P., Furniss, M. J., Robillard, K. A., Tomaszewski, J. E., & Parchment, R. E. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1113-7 · Cited by 3 · see citing works
Self-citationImproving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments
Gong, J., Bordeau, B. M., & Balthasar, J. P. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01087-w · Cited by 2 · see citing works
Preclinical Tumor Response End Points
Teicher, B. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_23 · Cited by 2 · see citing works
Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
Juvekar, A. S., Thompson, J., Stewart, C. F., & Houghton, P. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-866-8:127 · Cited by 2 · see citing works
Failure modes in anticancer drug discovery and development
Pearce, H. L., Blanchard, K. L., & Slapak, C. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50021-5 · Cited by 2 · see citing works
CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, Radicut, and STAZN)
Lapchak, P. A. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9530-8_31 · Cited by 1 · see citing works
In-vitro hematological toxicity prediction by colony-forming cell assays
Yadav, N. K., Shukla, P., Omer, A., & Singh, R. K. (2013) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-013-0172-7 · Cited by 1 · see citing works
Takamatsu, K., Wakata, A., Tabata, H., & Nishikata, T. (2012) · Comparative Clinical Pathology · doi:10.1007/s00580-012-1653-9 · Cited by 1 · see citing works
Intravenous administration of 9‐aminocamptothecin to dogs with lymphoma
Moore, A. S., Imondi, A. R., de Souza, P. L., & Wood, C. A. (2003) · Veterinary and Comparative Oncology · doi:10.1046/j.1476-5829.2003.00012.x · Cited by 1 · see citing works
Topoisomerase I Inhibitors: Chemical Biology
Teicher, B. A. (2011) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-0323-4_10 · Cited by 1 · see citing works
Dobrovolskaia, M. A., & McNeil, S. E. (2016) · Frontiers in nanobiomedical research · doi:10.1142/9789813140431_0012 · Cited by 1 · see citing works
Mouse Models of Leukemia: Pros and Cons
Shannon, K., Lowe, S. W., & Braun, B. S. (2008) · The Hematologist · doi:10.1182/hem.v5.4.6143 · Cited by 1 · see citing works
Tiwari, S. (2014) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 1 · see citing works
Hematotoxicity:In VitroandEx VivoCompound Profiling
Brott, D., & Pognan, F. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch17
Clinical Experience With 9-Aminocamptothecin
Takimoto, C. H. M. (2005) · Humana Press eBooks · doi:10.1385/1-59259-866-8:193
Recherche des anticancéreux : passé et présent
Pierré, A. (2005) · Annales Pharmaceutiques Françaises · doi:10.1016/s0003-4509(05)82245-x
- Authors
- Erickson-Miller, C. L., May, R. D., Tomaszewski, J., Osborn, B., Murphy, M. J., Page, J. G., & Parchment, R. E.
- Affiliations
- Southern Research Institute (US)
- National Institutes of Health (US)
- Hipple Cancer Research Center (US)
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1997-02-10
- Volume
- 39
- Issue
- 5
- Pages
- 467-472
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1995743646
- Cited by
- 111
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2021: 1 · 2019: 1 · 2018: 2 · 2017: 5 · 2016: 2 · 2015: 4 · 2014: 3 · 2013: 8 · 2012: 5
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01cm087259-000)
- National Cancer Institute (CM-07361, N01-CM-87259)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- camptothecin, topotecan, 9-aminocamptothecin, topoisomerase I inhibitor, myelosuppression, CFU-GM, myeloid progenitor cells, human-mouse differences, canine, hematopoietic toxicity, dose-limiting toxicity, drug tolerance, colony formation inhibition
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Bone Marrow Cells, Camptothecin, Cells, Cultured, Colony-Forming Units Assay, Dogs, Hematopoietic Stem Cells, Humans, Interleukin-3, Recombinant Proteins, Granulocyte-Macrophage Colony-Stimulating Factor, Topotecan, Mice, Topoisomerase II Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
